| PERSPECTIVE |
|
| Year : 2000 | Volume
: 1
| Issue : 7 | Page : 258-263 |
|
|
Newer orally active antiplatelet agents: DO they have an edge over aspirin?
Abhay K Pande, Kainal K Sethi
Dharma Vira Heart Centre, Sir Gangaram Hospital Rajinder nagar, New Delhi, India
Correspondence Address:
Abhay K Pande
B4/7 1, Azad Aparments, Sri Aurobindo Marg, Hauz Khas, New Delhi 110016
India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
An extensive body of research conducted in the past 25 years has helped foster understanding of the mechanisms and pathogenesis of the acute coronary syndromes and occlusive disease. The role of platelet and the endothelium in the pathogenesis of atherosclerosis and subsequent ischemic events is well established. The field of antiplatelet therapy is rapidly expanding with the availability of newer antiplatelet agents. However, at the present time, there is no convincing data available that other antiplatelet drugs are superior to aspirin. Aspirin remains the cornerstone of therapy for various ischemic disorders and the foundation on which other therapies are added, both in the short and long term.
|
|
|
|
| [PDF]* |
|
 |
|
